RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
EPIRUS Biopharmaceuticals Stock

EPIRUS Biopharmaceuticals ROE 2024

EPIRUS Biopharmaceuticals ROE

0

Ticker

EPRSQ

ISIN

US29428P1075

WKN

A117U3

In 2024, EPIRUS Biopharmaceuticals's return on equity (ROE) was 0, a 0% increase from the 0 ROE in the previous year.

EPIRUS Biopharmaceuticals Aktienanalyse

What does EPIRUS Biopharmaceuticals do?

EPIRUS Biopharmaceuticals Inc is an American biotech company specializing in the development of innovative drugs for the treatment of cancer and autoimmune diseases. It was founded in 2010 by Amit Munshi and is headquartered in Boston, Massachusetts. The company's business model is based on the use of biotechnology and advanced research and development to create specialized medications. EPIRUS aims to help patients with serious medical needs and contribute to improving healthcare worldwide. EPIRUS Biopharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding EPIRUS Biopharmaceuticals's Return on Equity (ROE)

EPIRUS Biopharmaceuticals's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing EPIRUS Biopharmaceuticals's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

EPIRUS Biopharmaceuticals's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in EPIRUS Biopharmaceuticals’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about EPIRUS Biopharmaceuticals stock

What is the ROE (Return on Equity) of EPIRUS Biopharmaceuticals this year?

The ROE of EPIRUS Biopharmaceuticals this year is 0 undefined.

How has the Return on Equity (ROE) of EPIRUS Biopharmaceuticals developed compared to the previous year?

The ROE of EPIRUS Biopharmaceuticals has increased by 0% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of EPIRUS Biopharmaceuticals?

A high ROE indicates that EPIRUS Biopharmaceuticals generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of EPIRUS Biopharmaceuticals?

A low ROE can indicate that EPIRUS Biopharmaceuticals is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of EPIRUS Biopharmaceuticals affect the company?

A change in ROE (Return on Equity) of EPIRUS Biopharmaceuticals can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of EPIRUS Biopharmaceuticals?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of EPIRUS Biopharmaceuticals?

Some factors that can influence EPIRUS Biopharmaceuticals's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does EPIRUS Biopharmaceuticals pay?

Over the past 12 months, EPIRUS Biopharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, EPIRUS Biopharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of EPIRUS Biopharmaceuticals?

The current dividend yield of EPIRUS Biopharmaceuticals is .

When does EPIRUS Biopharmaceuticals pay dividends?

EPIRUS Biopharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of EPIRUS Biopharmaceuticals?

EPIRUS Biopharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of EPIRUS Biopharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is EPIRUS Biopharmaceuticals located?

EPIRUS Biopharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von EPIRUS Biopharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of EPIRUS Biopharmaceuticals from 11/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/1/2024.

When did EPIRUS Biopharmaceuticals pay the last dividend?

The last dividend was paid out on 11/1/2024.

What was the dividend of EPIRUS Biopharmaceuticals in the year 2023?

In the year 2023, EPIRUS Biopharmaceuticals distributed 0 USD as dividends.

In which currency does EPIRUS Biopharmaceuticals pay out the dividend?

The dividends of EPIRUS Biopharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von EPIRUS Biopharmaceuticals

Our stock analysis for EPIRUS Biopharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of EPIRUS Biopharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.